Topical bioavailability through intact stratum corneum is poor for this hydrophilic tripeptide without a penetration enhancer, a fact most product pages omit entirely

Conservative combination protocol (if attempting) Rationale for conservative approach: No safety data available Both peptides slow gastric emptying significantly Risk of severe GI complications Start low, go slow principle Tirzepatide component: Follow standard FDA-approved titration Weeks 1-4: 2.5mg weekly Weeks 5-8: 5mg weekly Weeks 9-12: 7.5mg weekly Weeks 13-16: 10mg weekly Week 17+: 12.5mg weekly (or stay at 10mg) Some reach 15mg weekly (maximum) Cagrilintide component (reduced from standard): Start AFTER tirzepatide stabilized at therapeutic dose (week 13+) Week 13-16: 0.6mg weekly (lower than standard) Week 17-20: 1.2mg weekly Week 21-24: 1.8mg weekly (may be maximum tolerable) Consider 2.4mg only if tolerating perfectly Conservative dosing comparison: Why sequential is safer: Tirzepatide establishes baseline first Can attribute new side effects to cagrilintide Easier to manage one variable at a time Option to stop cagrilintide if intolerable Less overwhelming than both simultaneously Expected benefits: 18-25% total weight loss (conservative estimate) Potentially superior to tirzepatide alone (15-22%) But incremental benefit may be modest (3-5% additional) Use SeekPeptides to plan sequential peptide additions safely

Health Canada has stated that unauthorized injectable peptides cannot lawfully be compounded for human use, and the FDA's December 2024 PCAC review recommended against permitting AOD-9604 in 503A compounding in the United States
The researchers concluded that intranasal administration of DSIP, given both preventively and therapeutically over 8 days, leads to accelerated recovery of motor functions in SD rats after focal stroke
Combining 5-amino-1mq with powerful stimulants may produce unpredictable effects on heart rate, blood pressure, and nervous system function